Literature DB >> 33619261

Acute myeloid leukemia: current progress and future directions.

Hagop Kantarjian1, Tapan Kadia2, Courtney DiNardo2, Naval Daver2, Gautam Borthakur2, Elias Jabbour2, Guillermo Garcia-Manero2, Marina Konopleva2, Farhad Ravandi2.   

Abstract

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33619261      PMCID： PMC7900255          DOI： 10.1038/s41408-021-00425-3

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


  157 in total

1.  Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia.

Authors:  A-M Tsimberidou; E Estey; H Kantarjian; M J Keating; S Pierce; G Garcia-Manero
Journal:  Leukemia       Date:  2006-05-25       Impact factor: 11.528

2.  First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

Authors:  Eric J Feldman; Jeffrey E Lancet; Jonathan E Kolitz; Ellen K Ritchie; Gail J Roboz; Alan F List; Steven L Allen; Ekatherine Asatiani; Lawrence D Mayer; Christine Swenson; Arthur C Louie
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

3.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

Authors:  Yasmin Abaza; Hagop Kantarjian; Guillermo Garcia-Manero; Elihu Estey; Gautam Borthakur; Elias Jabbour; Stefan Faderl; Susan O'Brien; William Wierda; Sherry Pierce; Mark Brandt; Deborah McCue; Rajyalakshmi Luthra; Keyur Patel; Steven Kornblau; Tapan Kadia; Naval Daver; Courtney DiNardo; Nitin Jain; Srdan Verstovsek; Alessandra Ferrajoli; Michael Andreeff; Marina Konopleva; Zeev Estrov; Maria Foudray; David McCue; Jorge Cortes; Farhad Ravandi
Journal:  Blood       Date:  2016-12-21       Impact factor: 22.113

4.  A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.

Authors:  M A Sanz; G Martín; C Rayón; J Esteve; M González; J Díaz-Mediavilla; P Bolufer; E Barragán; M J Terol; J D González; D Colomer; C Chillón; C Rivas; T Gómez; J M Ribera; R Bornstein; J Román; M J Calasanz; J Arias; C Alvarez; F Ramos; G Debén
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

5.  Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.

Authors:  Tapan M Kadia; Stefan Faderl; Farhad Ravandi; Elias Jabbour; Guillermo Garcia-Manero; Gautam Borthakur; Alessandra Ferrajoli; Marina Konopleva; Jan Burger; Xuelin Huang; Xuemei Wang; Sherry Pierce; Mark Brandt; Jennie Feliu; Jorge Cortes; Hagop Kantarjian
Journal:  Cancer       Date:  2015-03-25       Impact factor: 6.860

6.  A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.

Authors: 
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

7.  Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.

Authors:  Francesco Lo-Coco; Giuseppe Cimino; Massimo Breccia; Nélida I Noguera; Daniela Diverio; Erica Finolezzi; Enrico M Pogliani; Eros Di Bona; Concetta Micalizzi; Mariagrazia Kropp; Adriano Venditti; Agostino Tafuri; Franco Mandelli
Journal:  Blood       Date:  2004-06-08       Impact factor: 22.113

8.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

Authors:  Rongqing Pan; Leah J Hogdal; Juliana M Benito; Donna Bucci; Lina Han; Gautam Borthakur; Jorge Cortes; Daniel J DeAngelo; Lakeisha Debose; Hong Mu; Hartmut Döhner; Verena I Gaidzik; Ilene Galinsky; Leonard S Golfman; Torsten Haferlach; Karine G Harutyunyan; Jianhua Hu; Joel D Leverson; Guido Marcucci; Markus Müschen; Rachel Newman; Eugene Park; Peter P Ruvolo; Vivian Ruvolo; Jeremy Ryan; Sonja Schindela; Patrick Zweidler-McKay; Richard M Stone; Hagop Kantarjian; Michael Andreeff; Marina Konopleva; Anthony G Letai
Journal:  Cancer Discov       Date:  2013-12-17       Impact factor: 39.397

9.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

Authors:  Steven M Chan; Daniel Thomas; M Ryan Corces-Zimmerman; Seethu Xavy; Suchita Rastogi; Wan-Jen Hong; Feifei Zhao; Bruno C Medeiros; David A Tyvoll; Ravindra Majeti
Journal:  Nat Med       Date:  2015-01-19       Impact factor: 87.241

10.  Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Authors:  Alexander E Perl; Jessica K Altman; Jorge Cortes; Catherine Smith; Mark Litzow; Maria R Baer; David Claxton; Harry P Erba; Stan Gill; Stuart Goldberg; Joseph G Jurcic; Richard A Larson; Chaofeng Liu; Ellen Ritchie; Gary Schiller; Alexander I Spira; Stephen A Strickland; Raoul Tibes; Celalettin Ustun; Eunice S Wang; Robert Stuart; Christoph Röllig; Andreas Neubauer; Giovanni Martinelli; Erkut Bahceci; Mark Levis
Journal:  Lancet Oncol       Date:  2017-06-20       Impact factor: 41.316
View more
  62 in total

Review 1.  Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.

Authors:  David C de Leeuw; Gert J Ossenkoppele; Jeroen J W M Janssen
Journal:  Curr Oncol Rep       Date:  2022-06-02       Impact factor: 5.075

Review 2.  The cure of leukemia through the optimist's prism.

Authors:  Hagop M Kantarjian; Nitin Jain; Guillermo Garcia-Manero; Mary Alma Welch; Farhad Ravandi; William G Wierda; Elias J Jabbour
Journal:  Cancer       Date:  2021-10-06       Impact factor: 6.860

Review 3.  Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.

Authors:  Hagop Kantarjian; Nicholas J Short; Courtney DiNardo; Eytan M Stein; Naval Daver; Alexander E Perl; Eunice S Wang; Andrew Wei; Martin Tallman
Journal:  Lancet Haematol       Date:  2021-10-20       Impact factor: 18.959

4.  Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4.

Authors:  Tianzhen Hu; Chengyun Pan; Tianzhuo Zhang; Ming Ni; Weili Wang; Siyu Zhang; Ying Chen; Jishi Wang; Qin Fang
Journal:  Cancer Gene Ther       Date:  2022-07-15       Impact factor: 5.854

5.  A bavachinin analog, D36, induces cell death by targeting both autophagy and apoptosis pathway in acute myeloid leukemia cells.

Authors:  Wen Zhang; Jingwen Liu; Yiming Li; Fujiang Guo
Journal:  Cancer Chemother Pharmacol       Date:  2022-08-12       Impact factor: 3.288

6.  Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis.

Authors:  Guanfang Liu; Qi Zhang; Jingying Yang; Xiaomin Li; Luhua Xian; Wenmin Li; Ting Lin; Juan Cheng; Qiwen Lin; Xiuzhang Xu; Qin Li; Yu Lin; Maohua Zhou; Erxia Shen
Journal:  Cancer Immunol Immunother       Date:  2021-06-15       Impact factor: 6.968

7.  The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial.

Authors:  Rosa Ayala; Inmaculada Rapado; Esther Onecha; David Martínez-Cuadrón; Gonzalo Carreño-Tarragona; Juan Miguel Bergua; Susana Vives; Jesus Lorenzo Algarra; Mar Tormo; Pilar Martinez; Josefina Serrano; Pilar Herrera; Fernando Ramos; Olga Salamero; Esperanza Lavilla; Cristina Gil; Jose Luis López Lorenzo; María Belén Vidriales; Jorge Labrador; José Francisco Falantes; María José Sayas; Bruno Paiva; Eva Barragán; Felipe Prosper; Miguel Ángel Sanz; Joaquín Martínez-López; Pau Montesinos
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

8.  DNMT3A Mutation-Induced CDK1 Overexpression Promotes Leukemogenesis by Modulating the Interaction between EZH2 and DNMT3A.

Authors:  Ying Yang; Yujun Dai; Xuejiao Yang; Songfang Wu; Yueying Wang
Journal:  Biomolecules       Date:  2021-05-22

Review 9.  The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities.

Authors:  Samantha Bruno; Manuela Mancini; Sara De Santis; Cecilia Monaldi; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

10.  Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.

Authors:  Tapan M Kadia; Patrick K Reville; Gautam Borthakur; Musa Yilmaz; Steven Kornblau; Yesid Alvarado; Courtney D Dinardo; Naval Daver; Nitin Jain; Naveen Pemmaraju; Nicholas Short; Sa A Wang; Rebecca S S Tidwell; Rabiul Islam; Marina Konopleva; Guillermo Garcia-Manero; Farhad Ravandi; Hagop M Kantarjian
Journal:  Lancet Haematol       Date:  2021-08       Impact factor: 30.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.